上海健麾信息技术股份有限公司全体股东： 我们接受委托，对后附的上海健麾信息技术股份有限公司（以下 简称"健麾信息"）2024年度募集资金存放与使用情况专项报告（以下 简称"募集资金专项报告"）执行了合理保证的鉴证业务。 上海健麾信息技术股份有限公司 鉴证报告 二〇二四年度 关于上海健麾信息技术股份有限公司 2024年度募集资金存放与使用情况专项报告的 鉴证报告 信会师报字[2025]第ZA12577号 一、董事会的责任 健麾信息董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）、《上海证券交易所 上市公司自律监管指引第1号——规范运作》以及《上海证券交易所 上市公司自律监管指南第1号——公告格式》的相关规定编制募集资 金专项报告。这种责任包括设计、执行和维护与募集资金专项报告编 制相关的内部控制，确保募集资金专项报告真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金专项报告发 表鉴证结论。 三、工作概述 我们按照《中国注册会计 ...

Financial Performance - The net profit attributable to the parent company's shareholders for 2024 is CNY 32,520,676.27[6]. - In 2024, the company's operating revenue increased by 3.51% year-on-year to CNY 318,349,489.92, while net profit attributable to shareholders decreased by 45.80% to CNY 32,520,676.27[24]. - The net profit excluding non-recurring gains and losses dropped by 62.07% year-on-year to CNY 17,145,709.78, reflecting significant challenges in the domestic market[26]. - Basic and diluted earnings per share fell by 45.45% to CNY 0.24, while the basic earnings per share after excluding non-recurring gains and losses decreased by 60.61% to CNY 0.13[25]. - The weighted average return on equity decreased by 2.76 percentage points to 3.06%, indicating a decline in profitability[25]. - The total assets at the end of 2024 reached CNY 1,466,011,224.89, an increase of 11.33% compared to the previous year[24]. - The net cash flow from operating activities improved significantly, reaching CNY 17,677,554.78, compared to a negative cash flow in 2023[24]. - The company reported a significant increase in revenue, achieving a total of $500 million for the quarter, representing a 25% year-over-year growth[149]. Dividend Policy - The company plans not to distribute cash dividends, issue bonus shares, or increase capital reserves for 2024[6]. - The company will not distribute cash dividends or issue new shares for 2024, opting to retain profits for R&D and business expansion[175]. - The company’s cash dividend ratio for the year is 0.00%, reflecting a strategy focused on long-term growth and investment in R&D[175]. - The cumulative cash dividend amount over the last three accounting years was RMB 25,840,000.00, representing a cash dividend ratio of 37.23% of the average annual net profit[180]. - There were no cash dividends or stock bonuses declared for the current reporting period[179]. Operational Efficiency - The company has strengthened its operational capabilities through strict budget execution and lean production management, improving overall operational efficiency[37]. - The company reported a significant improvement in accounts receivable management, leading to better cash collection compared to previous years[26]. - The net cash flow from operating activities improved significantly, reaching 17.68 million yuan, attributed to better accounts receivable management[74]. - The company has implemented intelligent drug management projects in over 1,000 hospitals across 31 provinces, enhancing brand recognition[69]. Market Expansion and Strategy - The company is actively expanding into emerging businesses such as intelligent distribution centers and logistics with mobile robots, although profit margins in these areas still need improvement[26]. - The company plans to continue focusing on market expansion and new technology development to enhance future performance[26]. - The company established a joint venture in Riyadh, Saudi Arabia, with Ajlan & Bros to promote its products in the Middle East and North Africa markets, aiming to enhance the digitalization and automation of the healthcare industry[34]. - The company is actively exploring the pharmaceutical retail market, planning to replicate the "smart pharmacy" model nationwide, integrating various product categories beyond pharmaceuticals[35]. - The company aims to expand its "to-G" business and overseas markets, particularly in the Middle East, Southeast Asia, and Europe, to increase its international influence and revenue share[123]. Research and Development - The company is increasing R&D investments to develop customized product solutions for overseas markets, enhancing its international brand influence and competitiveness[36]. - The R&D team has nearly 20 years of experience, enabling strong technical innovation and product development capabilities[65]. - The company plans to enhance its R&D capabilities and product development, focusing on market-oriented strategies and advanced technologies such as machine vision and deep learning[122]. - The company emphasizes the importance of R&D for maintaining competitive advantages in the pharmaceutical management sector[54]. Governance and Compliance - The report includes a standard unqualified audit opinion from Lixin Certified Public Accountants[5]. - The company emphasizes the importance of the accuracy and completeness of the financial report[5]. - The internal control system was evaluated as effective with no significant deficiencies reported for financial reporting[183]. - The company has not reported any major differences in governance compared to regulations set by the China Securities Regulatory Commission[142]. Risks and Challenges - The company has described potential risks in the report, urging investors to pay attention[9]. - The overall economic environment remains challenging, impacting the company's performance and necessitating ongoing strategic adjustments[33]. - In 2024, the company faced challenges due to delayed payments and bad debt provisions, resulting in performance not meeting expectations[33]. Shareholder Commitments - The company commits to not transferring or entrusting the management of shares held before the issuance for 36 months post-listing[196]. - The actual controller, Dai Jianwei, and the actual controller, Sun Dong, have both committed to not transferring shares for 36 months post-IPO[193]. - The commitments include provisions for adjustments in case of changes to regulations regarding share transfers[193]. - The company has ensured that all relevant legal and regulatory requirements are being adhered to in relation to share transfers and commitments[195].

Financial Performance - The company's operating revenue for Q1 2025 was ¥77,062,237.46, representing a 116.27% increase compared to ¥35,633,143.76 in the same period last year[4]. - Net profit attributable to shareholders decreased by 34.65% to ¥3,426,112.19 from ¥5,242,315.57 year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 30.93% to ¥3,293,843.93 compared to ¥4,768,546.05 in the previous year[4]. - The basic earnings per share decreased by 25.00% to ¥0.03 from ¥0.04 in the same period last year[6]. - Operating profit for Q1 2025 was ¥2,989,535.61, slightly down from ¥3,059,665.14 in Q1 2024, indicating a decrease of 2.3%[16]. - Net profit for Q1 2025 was ¥1,421,430.66, a decline of 39.7% from ¥2,357,351.02 in Q1 2024[16]. - Earnings per share for Q1 2025 were ¥0.03, compared to ¥0.04 in Q1 2024, reflecting a 25% decrease[17]. - The company reported a total operating cost of ¥70,665,174.04 for Q1 2025, up 105.6% from ¥34,358,791.33 in Q1 2024[15]. - The company recorded an investment loss of ¥3,135,299.41 in Q1 2025, slightly higher than the loss of ¥3,068,294.00 in Q1 2024[16]. Cash Flow and Assets - The net cash flow from operating activities improved to -¥28,754,383.31 from -¥64,638,160.26 year-on-year, indicating a reduction in cash payments for goods[4][8]. - Cash flow from operating activities for Q1 2025 was negative at -¥28,754,383.31, an improvement from -¥64,638,160.26 in Q1 2024[21]. - The company reported a decrease in cash and cash equivalents to RMB 80,918,614.87 from RMB 123,838,936.62, a decline of about 34.6%[11]. - The beginning balance of cash and cash equivalents was $121,835,498.45, down from $233,701,032.61 year-over-year[22]. - The ending balance of cash and cash equivalents stood at $80,317,242.86, a decrease from $153,157,170.00 compared to the previous period[22]. - Total assets at the end of the reporting period were ¥1,473,615,747.45, a slight increase of 0.52% from ¥1,466,011,224.89 at the end of the previous year[6]. - The company's total assets as of March 31, 2025, amount to RMB 1,473,615,747.45, an increase from RMB 1,466,011,224.89 at the end of 2024[12]. - Current assets total RMB 735,762,983.90, slightly down from RMB 748,323,890.23[12]. - Accounts receivable increased to RMB 463,092,641.05 from RMB 411,897,556.09, reflecting a growth of approximately 12.4%[11]. - Inventory decreased to RMB 71,694,634.53 from RMB 99,691,956.05, a decline of about 28.1%[12]. - Total liabilities increased to RMB 311,614,976.77 from RMB 305,431,884.87, indicating a rise of approximately 2.1%[13]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,423[10]. - The largest shareholder, Dai Jianwei, holds 57,113,219 shares, representing 42.00% of total shares[10]. - The number of shares held by the top 10 shareholders remains unchanged, indicating stability in shareholder structure[11]. - The company has no significant changes in its transfer and lending business, maintaining a stable operational environment[11]. Business Strategy and Market Conditions - The company is actively expanding into emerging businesses such as intelligent static distribution centers and logistics with mobile robots, although profit margins in these areas still need improvement[8]. - The company reported a significant impact from the global economic slowdown and reduced domestic market demand, affecting overall profitability[8]. - The company plans to focus on market expansion and new product development in the upcoming quarters[15]. - Research and development expenses for Q1 2025 were ¥4,821,605.40, down 27% from ¥6,600,012.24 in Q1 2024[15].

上海健麾信息技术股份有限公司 内部控制审计报告 二〇二四年度 内控审计报告 第1页 内部控制审计报告 信会师报字[2025]第 ZA12575 号 上海健麾信息技术股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的 相关要求，我们审计了上海健麾信息技术股份有限公司（以下简称 健麾信息）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、 《企业内部控制评价指引》的规定，建立健全和有效实施内部控制， 并评价其有效性是健麾信息董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制 的有效性发表审计意见，并对注意到的非财务报告内部控制的重大 缺陷进行披露。 三、 内部控制的固有局限性 内控审计报告 第1页 四、 财务报告内部控制审计意见 我们认为，健麾信息于 2024 年 12 月 31 日按照《企业内部控制 基本规范》和相关规定在所有重大方面保持了有效的财务报告内部 控制。 立信会计师事务所 中国注册会计师： （特殊普通合伙） 中国注册会计师： 中国•上 ...

目 录 1、 专项审计报告 关于上海健麾信息技术股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 2、 附表 委托单位：上海健麾信息技术股份有限公司 审计单位：立信会计师事务所（特殊普通合伙） 联系电话：021-23281358 立信会计师事务所(特殊普通合伙) BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 关于上海健麾信息技术股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZA12576 号 上海健磨信息技术股份有限公司全体股东: 我们审计了上海健磨信息技术股份有限公司(以下简称"健慶信 息")2024年度的财务报表,包括2024年12月31日的合并及母公司 资产负债表、2024年度合并及母公司利润表、合并及母公司现金流。 量表、合并及母公司所有者权益变动表和相关财务报表附注,并于 2025 年 4 月 28 日出具了报告号为信会师报字【2025】第 ZA12574 号的无保留意见审计报告。 键確信息管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号 -- 上市公 ...

上海健麾信息技术股份有限公司的主营业务为医疗服务和医药流通行业的药品智能化管理提供相应的产 品及服务。公司的主要产品是智慧药房项目、智能化静配中心项目、智能化药品耗材管理项目。公司已 于800余家医院实施了各类智能化药品管理项目，范围遍布29个省、自治区及直辖市，包括北京协和医 院在内的众多知名医疗服务机构均使用公司的产品，使公司的品牌优势不断积累。 最新一期业绩显示，2024年三季报，公司实现营业收入1.95亿元，同比-19.07%；净利润3205.15万元， 同比-56.71%，销售毛利率57.35%。 4月21日，健麾信息今日收盘18.69元，上涨1.25%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到141.18倍，总市值25.42亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均46.70倍，行业中值48.76倍，健麾信息排 名第40位。 股东方面，截至2024年9月30日，健麾信息股东户数12211户，较上次增加1198户，户均持股市值35.28 万元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)40健麾信息141.1842.362 ...

Core Viewpoint - The company Jianhui Information has experienced a decline in stock price and financial performance, with a high PE ratio compared to the industry average, indicating potential overvaluation in the context of its recent earnings report [1][2]. Company Summary - Jianhui Information's stock closed at 18.22 yuan, down 3.44%, with a rolling PE ratio of 137.63 times and a total market capitalization of 2.478 billion yuan [1]. - The company operates in the medical services and pharmaceutical distribution sector, providing intelligent management products and services for drug management [1]. - Major products include smart pharmacy projects, intelligent central preparation centers, and intelligent drug consumables management projects, implemented in over 800 hospitals across 29 provinces and municipalities [1]. - The latest financial results for Q3 2024 show revenue of 195 million yuan, a year-on-year decrease of 19.07%, and a net profit of 32.05 million yuan, down 56.71%, with a gross margin of 57.35% [1]. Industry Summary - The average PE ratio for the medical services industry is 45.05 times, with a median of 46.97 times, positioning Jianhui Information at the 40th rank within the industry [2]. - A total of 19 institutions hold shares in Jianhui Information, all of which are funds, with a combined holding of 710,800 shares valued at 1.4 million yuan [1].

4月7日，健麾信息今日收盘18.48元，下跌9.99%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到139.59倍，总市值25.13亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均45.72倍，行业中值41.83倍，健麾信息排 名第40位。 截至2024年三季报，共有19家机构持仓健麾信息，其中基金19家，合计持股数71.08万股，持股市值0.14 亿元。 上海健麾信息技术股份有限公司的主营业务为医疗服务和医药流通行业的药品智能化管理提供相应的产 品及服务。公司的主要产品是智慧药房项目、智能化静配中心项目、智能化药品耗材管理项目。公司已 于800余家医院实施了各类智能化药品管理项目，范围遍布29个省、自治区及直辖市，包括北京协和医 院在内的众多知名医疗服务机构均使用公司的产品，使公司的品牌优势不断积累。 最新一期业绩显示，2024年三季报，公司实现营业收入1.95亿元，同比-19.07%；净利润3205.15万元， 同比-56.71%，销售毛利率57.35%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)40健麾信息139.5941.892.3525.13亿行业平均 4 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Jianhui Information, which operates in the medical services and pharmaceutical distribution sector, showcasing its growth and challenges in the current market environment [1][2] - As of April 1, Jianhui Information's stock closed at 20.49 yuan, with a PE ratio of 154.78, significantly higher than the industry average of 52.86 [1][2] - The company has a total market capitalization of 2.787 billion yuan, ranking 40th in the medical services industry based on PE ratio [1][2] Group 2 - Jianhui Information reported a revenue of 195 million yuan for the third quarter of 2024, reflecting a year-on-year decrease of 19.07%, while net profit fell by 56.71% to 32.05 million yuan [1] - The company's gross profit margin stands at 57.35%, indicating its ability to maintain profitability despite declining revenues [1] - The company has implemented various intelligent drug management projects in over 800 hospitals across 29 provinces, enhancing its brand recognition and market presence [1]